Search for: "Eli Lilly "
Results 401 - 420
of 2,147
Sort by Relevance
|
Sort by Date
9 Nov 2017, 1:55 am
Entrance to the Swiss Federal Supreme CourtSince we are on the topic of K = Na, here a short update on the Swiss arm of the litigation.The Swiss Federal Patent Court considered the prosecution history and denied infringement of Eli Lilly’s patent by equivalent means because of the limitation introduced by the patentee during the examination. [read post]
8 Nov 2017, 10:48 pm
THE VOTE - has the decision in Actavis v Eli Lilly improved the law? [read post]
8 Nov 2017, 5:29 am
Part 2 covers claims with numerical limits, relevance of the file history, harmonisation, and a vote as to whether the decision in Actavis v Eli Lilly has improved the law. [read post]
7 Nov 2017, 11:36 am
The most recent medical journal article we have seen concerning this drug safety issue singles out the SGLT2 inhibitors which contain the active empagliflozin, which are listed below: Jardiance (empagliflozin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2014 Glyxambi (empagliflozin and linagliptin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2015 Synjardy (empagliflozin and metformin hydrochloride) — Boehringer Ingelheim Pharmaceuticals and… [read post]
7 Nov 2017, 3:26 am
It is not known whether Eli Lilly will seek to obtain permission to appeal from the Supreme Court. [read post]
31 Oct 2017, 12:05 am
Patent practitioners have been speculating in recent weeks about what the Actavis v Eli Lilly Supreme Court judgment means in practice and how that decision might be applied. [read post]
28 Oct 2017, 8:57 am
Citing CJEU case law (C-322/10 ”Medeva” and C-493/12 ”Eli Lilly”) as well as the DKPTO Guide Lines on SPCs – which state that a combination product consisting in the two active ingredients A and B are considered as protected, when A and B are stated in a patent claim – the Court concluded that ”Emtricitabin does not appear in the wording of claim 27, just as emtricitabin is not described by way of chemical name or structural formula or… [read post]
26 Oct 2017, 7:31 am
Brian Corderyby Rachel Mumby Patent lawyers in the UK have spent the last three months pondering, debating and at times indulging in an element of despair (to put it mildly) about what might be the impact of the judgment of the Supreme Court in Actavis v Eli Lilly [2017] UKSC 48 on issues of validity (see here). [read post]
25 Oct 2017, 6:55 am
Defendant Eli Lilly is a multinational pharmaceutical company based in Indianapolis. [read post]
24 Oct 2017, 8:33 am
In this guest post, she shares her thoughts and updates us on the related developments.Pemetrexed pops up in MilanGuest Kat Eibhlin gives takes us through the recent decision handed down by the Court of Milan which forms part of the long running multi-jurisdictional battle concerning Eli Lilly's patent protecting its pemetrexed (Alimta) product.Medical data in a twist - Technomed v BluecrestGuest Kat Rosie demystifies database rights with the recent decision of Technomed v… [read post]
18 Oct 2017, 5:33 pm
The second panelist, Jonathon Anderson, patent counsel with Eli Lilly, then addressed the session on some specific IP considerations for digital health businesses, considered particularly from the perspective of an established pharmaceutical/medical devices company. [read post]
17 Oct 2017, 6:09 pm
The panel members were Mattias Zigann, the presiding judge of the Munich Regional Court, Philip Kerr of Allens Linklaters and Larry Welch, the Senior Director, and Assistant General Patent Counsel at Eli Lilly and Company.Mr Ludwig explained that the question of what relief was appropriate had been highlighted by the very recent decision of the United States Court of Appeals for the Federal Circuit in AMGEN INC & ors v. [read post]
16 Oct 2017, 2:57 am
” In its recent judgment of 2 October 2017 (Eli Lilly v. [read post]
10 Oct 2017, 7:30 am
Although sales of Alimta have dropped in recent months, the cancer treatment remains an important part of Eli Lilly’s portfolio. [read post]
10 Oct 2017, 7:30 am
On Thursday, October 5th, a final written decision issued by the Patent Trial and Appeal Board (PTAB) upheld a series of 22 claims from a patent owned by Indianapolis, IN-based drugmaker Eli Lilly & Company (NYSE:LLY). [read post]
6 Oct 2017, 2:34 pm
Eli Lilly, the court reaffirmed that written description is determined based on the state of the art as of a patent’s priority date and that evidence which illuminates the state of the art only subsequent to the priority date is not relevant to written description. [read post]
6 Oct 2017, 2:34 pm
Eli Lilly, the court reaffirmed that written description is determined based on the state of the art as of a patent’s priority date and that evidence which illuminates the state of the art only subsequent to the priority date is not relevant to written description. [read post]
4 Oct 2017, 6:00 am
Nathan Yaffe, Transnational Arbitral Res JudicataSilke Noa Kumpf, Equity-Based Discretion and the Anatomy of Damages Assessment in Investment Treaty LawBoris Kasolowsky, Eric Leikin, Eli Lilly v. [read post]
1 Oct 2017, 9:43 pm
Eli Lilly (2010) (en banc). [read post]
27 Sep 2017, 9:01 pm
McKinney, who received a bachelor’s degree in agricultural economics in 1981, previously was director of global corporate affairs for Elanco Animal Health, a subsidiary of Eli Lilly and Company. [read post]
